Table 3 Regression-adjusted estimates of expenditures, prescription drug use, and adherence to medications stratified by type of medicare part D coverage (n = 344,817)

  Total expenditures

$1,887^a,b

$1,360^a

$1,341

(1,864-1,910)

(1,344-1,375)

(1,336-1,347)

  Out-of-pocket expenditures

$148^a,b

$546^a

$570

(146–150)

(539–552)

(567–572)

  Plan expenditures^c

$1,708^a,b

$822^a

$776

(1,687-1,729)

(811–833)

(772–780)

Expenditures on brand name medications

  Total expenditures

$1,325^a,b

$926^a

$898

(1,305-1,346)

(911–941)

(893–903)

  Out-of-pocket expenditures

$96^a,b

$374^a

$369

(94–98)

(368–381)

(367–371)

  Plan expenditures^c

$1,221^a,b

$560^a

$537

(1,202-1,240)

(549–571)

(533–540)

Expenditures exceeding the gap threshold

27.6%^a,b

17.4%^a

16.9%

(27.2-28.1)

(17.0-17.8)

(16.8-17.0)

Prescriptions

  Total number of prescriptions

38.1^a,b

25.1^a

26.5

(37.8-38.4)

(24.9-25.3)

(26.4-26.5)

  Total number of brand name prescriptions

10.7^a,b

6.4^a

6.9

(10.5-10.8)

(6.3-6.5)

(6.87-6.92)

Adherence to medications

  Diabetes drug adherence

62.5%^a,b

57.7%

57.4%

(61.0-63.9)

(56.0-59.4)

(56.9-58.0)

  Hypertension drug adherence

65.6%^a,b

64.2%^a

62.4%

(64.9-66.3)

(63.5-64.9)

(62.2-62.6)

  Lipid-lowering drug adherence

59.6%^a,b

57.0%^a

55.6%

(58.5-60.6)

(56.0-58.0)

(55.3-55.9)